EUVIMEDOpdag EUVIMED
Crossref

Tanshinone IIA Reverses Osteogenic Differentiation of Bone Marrow Mesenchymal Stromal Cells Impaired by Glucocorticoids via the ERK1 /2‐ CREB Signaling Pathway

Xiaodong Li, Xinyue Yang, Zelin Liu, Hongpeng Liu, Hang Lv, Xue Li, Xilin Xu, Yiwei Shen

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70069 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2025. Written by Xiaodong Li and 7 co-authors. Institution: The Third Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China. Major MEDLINE topics: Mesenchymal Stem Cells, Osteogenesis, Abietanes, Cyclic AMP Response Element-Binding Protein. Cited 5 times so far (Crossref); 63 references. Funded by: National Program Package for Heilongjiang University of Traditional Chinese Medicine, Young Innovative Talent Program of Ordinary Undergraduate Higher Education Institutions in Heilongjiang Province.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Glucocorticoids‐induced osteoporosis poses a critical health issue due to its detrimental impact on bone marrow mesenchymal stem cells (BMSCs); Tanshinone IIA (TSA) emerges as a promising therapeutic intervention, demonstrating its capacity to reverse osteogenic differentiation impairment. The aim is to determine whether TSA enhances the osteogenic differentiation of BMSCs damaged by dexamethasone (DEX) through the ERK1/2 –CREB signaling pathway. BMSCs were treated with varying concentrations of DEX (0.1–30 μM) and TSA (0.04–5 μM) for 18 or 36 h. Cell viability was assessed using the MTT assay. Osteogenic differentiation was evaluated through Alizarin Red S staining and quantified by qRT‐PCR for osteogenic markers such as Runx2 and ALP. Apoptosis was measured by Annexin V‐FITC/PI staining and TUNEL/DAPI co‐staining. The ERK1/2‐CREB signaling pathway was examined using Western blot and immunofluorescence. TSA at 5 μM significantly bolstered BMSCs viability and osteogenic differentiation, reversing the deleterious effects of 30 μM DEX. TSA pre‐treatment decreased apoptosis and ROS levels, and importantly, it enhanced the ERK1/2‐CREB signaling pathway, as evidenced by increased phosphorylation of ERK1/2 and CREB. The ERK1/2 inhibitor PD98059 and siCREB abrogated TSA's protective effects, highlighting the pathway's significance. These findings indicate that TSA, through the ERK1/2‐CREB axis, provides a protective strategy against DEX‐induced impairment in BMSCs. TSA's modulation of the ERK1/2 –CREB pathway reverses DEX‐induced osteogenic inhibition and apoptosis in BMSCs, suggesting its therapeutic efficacy against glucocorticoid‐induced bone disorders.

Subjects

MeSH terms (MEDLINE)

Mesenchymal Stem CellsOsteogenesisAbietanesCyclic AMP Response Element-Binding ProteinCell DifferentiationGlucocorticoidsMAP Kinase Signaling SystemDexamethasoneApoptosisAnimalsCell SurvivalCells, CulturedSignal TransductionHumans

Author keywords

ERK1/2‐CREB signaling pathwaybone marrow mesenchymal stromal cellsdexamethasoneosteogenic differentiation

Substances

tanshinoneAbietanesCyclic AMP Response Element-Binding ProteinGlucocorticoidsDexamethasone

Authors and institutions

  • The Third Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
  • The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
  • Shanhe YiPa Research Institute, Tianjin, China.
  • Binhai New Area Hospital of TCM, Tianjin (Fourth Teaching Hospital of Tian Jin University of TCM), Binhai New Area, Tianjin, China.

Funding

  • National Program Package for Heilongjiang University of Traditional Chinese Medicine
  • Young Innovative Talent Program of Ordinary Undergraduate Higher Education Institutions in Heilongjiang Province

Cite

APA

Li, X., Yang, X., Liu, Z., Liu, H., Lv, H., Li, X., Xu, X., & Shen, Y. (2025). Tanshinone IIA Reverses Osteogenic Differentiation of Bone Marrow Mesenchymal Stromal Cells Impaired by Glucocorticoids via the ERK1 /2‐ CREB Signaling Pathway. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70069

Vancouver

Li X, Yang X, Liu Z, Liu H, Lv H, Li X, et al. Tanshinone IIA Reverses Osteogenic Differentiation of Bone Marrow Mesenchymal Stromal Cells Impaired by Glucocorticoids via the ERK1 /2‐ CREB Signaling Pathway. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70069

BibTeX
@article{Li2025,
  author = {Li, Xiaodong and Yang, Xinyue and Liu, Zelin and Liu, Hongpeng and Lv, Hang and Li, Xue and Xu, Xilin and Shen, Yiwei},
  title = {Tanshinone IIA Reverses Osteogenic Differentiation of Bone Marrow Mesenchymal Stromal Cells Impaired by Glucocorticoids via the ERK1 /2‐ CREB Signaling Pathway},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70069}
}
Start for free →